Lundbeck's Vyepti Sales Pick Up Against Pandemic Headwinds

Lundbeck also makes progress in the third quarter with its early clinical-stage neuroscience candidates and indication extension studies for its psychiatry products, while confirming and narrowing  revenues and earnings forecasts for the year.